JP2007500720A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007500720A5 JP2007500720A5 JP2006522096A JP2006522096A JP2007500720A5 JP 2007500720 A5 JP2007500720 A5 JP 2007500720A5 JP 2006522096 A JP2006522096 A JP 2006522096A JP 2006522096 A JP2006522096 A JP 2006522096A JP 2007500720 A5 JP2007500720 A5 JP 2007500720A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- independently selected
- group
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims 94
- 239000001257 hydrogen Substances 0.000 claims 94
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 64
- 125000003710 aryl alkyl group Chemical group 0.000 claims 36
- 125000000217 alkyl group Chemical group 0.000 claims 35
- 125000000753 cycloalkyl group Chemical group 0.000 claims 33
- 125000001072 heteroaryl group Chemical group 0.000 claims 32
- 125000000623 heterocyclic group Chemical group 0.000 claims 32
- 125000003118 aryl group Chemical group 0.000 claims 30
- 150000002431 hydrogen Chemical class 0.000 claims 30
- -1 chloro, methyl Chemical group 0.000 claims 28
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 25
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 25
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims 20
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 18
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 18
- 125000005020 hydroxyalkenyl group Chemical group 0.000 claims 18
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 16
- 125000001153 fluoro group Chemical group F* 0.000 claims 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 15
- 125000005843 halogen group Chemical group 0.000 claims 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 108010087894 Fatty acid desaturases Proteins 0.000 claims 10
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 125000003367 polycyclic group Chemical group 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 7
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 6
- 230000005856 abnormality Effects 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 230000002159 abnormal effect Effects 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- IIFDQESZTDBKEM-UHFFFAOYSA-N 3-(4-fluorophenyl)propan-1-amine Chemical compound NCCCC1=CC=C(F)C=C1 IIFDQESZTDBKEM-UHFFFAOYSA-N 0.000 claims 2
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims 2
- 101000631826 Homo sapiens Stearoyl-CoA desaturase Proteins 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 102000055981 human SCD1 Human genes 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 1
- CKLFJWXRWIQYOC-UHFFFAOYSA-N 2-(4-fluorophenyl)ethanamine Chemical compound NCCC1=CC=C(F)C=C1 CKLFJWXRWIQYOC-UHFFFAOYSA-N 0.000 claims 1
- IMLAIXAZMVDRGA-UHFFFAOYSA-N 2-phenoxyethanamine Chemical compound NCCOC1=CC=CC=C1 IMLAIXAZMVDRGA-UHFFFAOYSA-N 0.000 claims 1
- LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- FGOUAQGATIHMQX-UHFFFAOYSA-N n-(2-phenylethyl)-5-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyrimidine-2-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2C=NC(=NC=2)C(=O)NCCC=2C=CC=CC=2)CC1 FGOUAQGATIHMQX-UHFFFAOYSA-N 0.000 claims 1
- DAXBFBDXGVPOQZ-UHFFFAOYSA-N n-(3-methylbutyl)-2-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NCCC(C)C)=CN=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 DAXBFBDXGVPOQZ-UHFFFAOYSA-N 0.000 claims 1
- BDBOKIVURAOEDF-UHFFFAOYSA-N n-(3-methylbutyl)-4-(trifluoromethyl)-2-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyrimidine-5-carboxamide Chemical compound N1=C(C(F)(F)F)C(C(=O)NCCC(C)C)=CN=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 BDBOKIVURAOEDF-UHFFFAOYSA-N 0.000 claims 1
- UVTGETXCJPTQCB-UHFFFAOYSA-N n-(3-phenylpropyl)-5-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyrimidine-2-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2C=NC(=NC=2)C(=O)NCCCC=2C=CC=CC=2)CC1 UVTGETXCJPTQCB-UHFFFAOYSA-N 0.000 claims 1
- PNQGAOSCJVLAFG-UHFFFAOYSA-N n-benzyl-5-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyrimidine-2-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2C=NC(=NC=2)C(=O)NCC=2C=CC=CC=2)CC1 PNQGAOSCJVLAFG-UHFFFAOYSA-N 0.000 claims 1
- OWUBZQNYYJEHEA-UHFFFAOYSA-N n-hexyl-5-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyrimidine-2-carboxamide Chemical compound C1=NC(C(=O)NCCCCCC)=NC=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 OWUBZQNYYJEHEA-UHFFFAOYSA-N 0.000 claims 1
- GADNSTZHYHGPJE-UHFFFAOYSA-N n-pentyl-5-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyrazine-2-carboxamide Chemical compound C1=NC(C(=O)NCCCCC)=CN=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 GADNSTZHYHGPJE-UHFFFAOYSA-N 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 0 CC1=*I=C(N(C*2)C(*)(*)C(*)(*)N(**)C2(*)C2*=C2)N=I1 Chemical compound CC1=*I=C(N(C*2)C(*)(*)C(*)(*)N(**)C2(*)C2*=C2)N=I1 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- HWCKAMAVEWVBDO-UHFFFAOYSA-N 5-chloropyrazin-2-amine Chemical compound NC1=CN=C(Cl)C=N1 HWCKAMAVEWVBDO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49109503P | 2003-07-30 | 2003-07-30 | |
| US60/491,095 | 2003-07-30 | ||
| PCT/US2004/024658 WO2005011657A2 (en) | 2003-07-30 | 2004-07-29 | Piperazine derivatives and their use as therapeutic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007500720A JP2007500720A (ja) | 2007-01-18 |
| JP2007500720A5 true JP2007500720A5 (enExample) | 2007-09-13 |
| JP4838128B2 JP4838128B2 (ja) | 2011-12-14 |
Family
ID=34115467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522096A Expired - Fee Related JP4838128B2 (ja) | 2003-07-30 | 2004-07-29 | ピペラジン誘導体および治療剤としてのその用途 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7456180B2 (enExample) |
| EP (2) | EP2316828A1 (enExample) |
| JP (1) | JP4838128B2 (enExample) |
| KR (1) | KR20060037409A (enExample) |
| CN (3) | CN1829701A (enExample) |
| AT (1) | ATE532772T1 (enExample) |
| AU (2) | AU2004261268B2 (enExample) |
| BR (1) | BRPI0412348A (enExample) |
| CA (1) | CA2533901A1 (enExample) |
| EC (1) | ECSP066311A (enExample) |
| ES (1) | ES2377406T3 (enExample) |
| IL (1) | IL173396A0 (enExample) |
| MA (1) | MA28010A1 (enExample) |
| NO (1) | NO20060971L (enExample) |
| PL (1) | PL1651620T3 (enExample) |
| PT (1) | PT1651620E (enExample) |
| RU (1) | RU2006105717A (enExample) |
| SG (1) | SG145701A1 (enExample) |
| SI (1) | SI1648874T1 (enExample) |
| TN (1) | TNSN06033A1 (enExample) |
| WO (1) | WO2005011657A2 (enExample) |
| ZA (2) | ZA200600125B (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517884B2 (en) | 1998-03-30 | 2009-04-14 | Kalypsys Inc. | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
| JP5048201B2 (ja) | 2000-08-04 | 2012-10-17 | ディーエムアイ バイオサイエンシズ インコーポレイテッド | ジケトピペラジン類の使用方法とジケトピペラジン類を含む組成物 |
| CN102210852B (zh) | 2003-05-15 | 2016-10-19 | 安皮奥制药股份有限公司 | T-细胞介导的疾病的治疗 |
| ES2327684T3 (es) | 2003-07-24 | 2009-11-02 | Euro-Celtique S.A. | Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor. |
| EP2316827B1 (en) | 2003-07-30 | 2016-01-27 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
| US7754711B2 (en) * | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| US7759348B2 (en) | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| ES2397389T3 (es) * | 2003-07-30 | 2013-03-06 | Xenon Pharmaceuticals Inc. | Derivados de piridilo y su uso como agentes terapéuticos |
| US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
| US7767677B2 (en) | 2004-09-20 | 2010-08-03 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| JP4958787B2 (ja) * | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体 |
| EP1804799B1 (en) | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| EP1799667B1 (en) | 2004-09-20 | 2013-03-20 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
| CA2580856A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| EP2316458A1 (en) * | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| EP2289510A1 (en) | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| CN101083986A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途 |
| RU2384576C2 (ru) | 2004-10-29 | 2010-03-20 | Калипсис, Инк | Сульфонил-замещенные бициклические соединения в качестве модуляторов ppar |
| EP1866314B1 (en) | 2005-02-16 | 2010-09-15 | NeuroSearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
| MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| WO2007044085A2 (en) * | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
| WO2006125179A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic compounds and their uses as therapeutic agents |
| WO2006125180A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
| WO2006125178A2 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic pyridazine compounds and their uses as therapeutic agents |
| WO2007046867A2 (en) * | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their uses as therapeutic agents |
| WO2006125181A2 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their use as stearoyl-coa desaturase modulators |
| WO2006125194A2 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
| EP2029138A1 (en) | 2005-06-03 | 2009-03-04 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| KR101464767B1 (ko) | 2005-10-25 | 2014-11-24 | 칼립시스, 인코포레이티드 | Ｐｐａｒ의 조절자의 염 및 대사질환을 치료하는 방법 |
| AU2006315025A1 (en) * | 2005-11-15 | 2007-05-24 | Merck Frosst Canada Ltd. | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2007071023A1 (en) * | 2005-12-20 | 2007-06-28 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| AR059355A1 (es) | 2006-02-07 | 2008-03-26 | Wyeth Corp | Inhibidores de 11-beta hsd1 |
| DE602007010287D1 (de) | 2006-06-05 | 2010-12-16 | Novartis Ag | Organische verbindungen |
| WO2008003753A1 (en) * | 2006-07-07 | 2008-01-10 | Biovitrum Ab (Publ) | Pyrazolo [1,5-a] pyrimidine analogs for use as inhibitors of stearoyl-coa desaturase (scd) activity |
| BRPI0719122A2 (pt) | 2006-08-24 | 2013-12-10 | Novartis Ag | Compostos orgânicos |
| RU2009112397A (ru) * | 2006-10-05 | 2010-10-10 | Си Ви ТЕРАПЬЮТИКС, ИНК (US) | Бициклические азотсодержащие гетероциклические соединения для применения в качестве ингибиторов стеароил соа десатуразы |
| EP2073806B1 (en) | 2006-10-12 | 2012-02-15 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| WO2008091863A1 (en) | 2007-01-23 | 2008-07-31 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| AR064965A1 (es) * | 2007-01-26 | 2009-05-06 | Merck Frosst Canada Inc | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
| WO2008096746A1 (ja) | 2007-02-06 | 2008-08-14 | Takeda Pharmaceutical Company Limited | スピロ化合物およびその用途 |
| JP2008239616A (ja) * | 2007-02-28 | 2008-10-09 | Iyaku Bunshi Sekkei Kenkyusho:Kk | Ｈｄｌ上昇剤 |
| US20080255153A1 (en) * | 2007-03-28 | 2008-10-16 | Biovitrum Ab (Publ) | New compounds |
| WO2008120759A1 (ja) * | 2007-03-30 | 2008-10-09 | Japan Tobacco Inc. | ウレア化合物およびその用途 |
| EP2142529B1 (en) * | 2007-04-27 | 2013-12-25 | Purdue Pharma LP | Trpv1 antagonists and uses thereof |
| WO2008143914A1 (en) | 2007-05-16 | 2008-11-27 | The University Of Maryland, College Park | Novel methods for recovery of leaf proteins |
| US7842696B2 (en) * | 2007-06-21 | 2010-11-30 | Forest Laboratories Holdings Limited | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase |
| GB0715055D0 (en) * | 2007-08-02 | 2007-09-12 | Smithkline Beecham Corp | Compounds |
| CN101821234B (zh) | 2007-08-08 | 2014-06-25 | 格里斯威医药有限责任公司 | 苯氧基吡咯烷衍生物及其应用和组合物 |
| WO2009037542A2 (en) | 2007-09-20 | 2009-03-26 | Glenmark Pharmaceuticals, S.A. | Spirocyclic compounds as stearoyl coa desaturase inhibitors |
| ES2499018T3 (es) * | 2007-09-20 | 2014-09-26 | Irm Llc | Compuestos y composiciones como moduladores de la actividad de GPR119 |
| GB0722077D0 (en) * | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| AU2009225513C1 (en) * | 2008-03-20 | 2012-01-12 | Forest Laboratories Holdings Limited | Novel piperazine derivatives as inhibitors of stearoyl-CoA desaturase |
| JP5856843B2 (ja) | 2008-05-27 | 2016-02-10 | アンピオ ファーマシューティカルズ，インコーポレイテッド | ジケトピペラジンを用いた医薬組成物 |
| HRP20150882T1 (hr) | 2008-10-17 | 2015-09-25 | Xenon Pharmaceuticals Inc. | Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva |
| WO2010045197A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| US20100160323A1 (en) * | 2008-12-23 | 2010-06-24 | Alexander Bischoff | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE |
| WO2010094120A1 (en) | 2009-02-17 | 2010-08-26 | Merck Frosst Canada Ltd. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| GB0907425D0 (en) * | 2009-04-29 | 2009-06-10 | Glaxo Group Ltd | Compounds |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| US8383643B2 (en) | 2009-07-28 | 2013-02-26 | Merck Canada Inc. | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
| WO2011030139A1 (en) | 2009-09-11 | 2011-03-17 | Astrazeneca Ab | 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators |
| PE20170202A1 (es) | 2009-10-14 | 2017-03-24 | Xenon Pharmaceuticals Inc | Metodos sinteticos para compuestos espiro-oxoindol |
| RU2596488C2 (ru) | 2010-02-26 | 2016-09-10 | Ксенон Фармасьютикалз Инк. | Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов |
| EP2613786A4 (en) | 2010-09-07 | 2013-10-23 | Dmi Acquisition Corp | TREATMENT OF DISEASES |
| RS55701B1 (sr) | 2011-06-22 | 2017-07-31 | Purdue Pharma Lp | Trpv1 antagonisti koji uključuju dihidroksi supstituent i njihove upotrebe |
| PH12014500685B1 (en) | 2011-10-10 | 2018-10-03 | Ampio Pharmaceuticals Inc | Treatment of degenerative joint disease |
| JP2014530063A (ja) | 2011-10-10 | 2014-11-17 | アンピオ ファーマシューティカルズ，インコーポレイテッド | 免疫寛容が高められた埋込み型医療用デバイス、ならびに製造方法および埋込み方法 |
| HK1198812A1 (en) | 2011-10-28 | 2015-06-12 | Ampio Pharmaceuticals, Inc. | Treatment of rhinitis |
| WO2013134546A1 (en) | 2012-03-07 | 2013-09-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| MX2014014174A (es) | 2012-05-22 | 2015-07-06 | Hoffmann La Roche | Inhibidores selectivos de celulas no diferenciadas. |
| CA2906864A1 (en) | 2013-03-15 | 2014-09-18 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
| UA117779C2 (uk) | 2014-02-14 | 2018-09-25 | Такеда Фармасьютікал Компані Лімітед | Піразини як модулятори gpr6 |
| WO2016022955A1 (en) | 2014-08-07 | 2016-02-11 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| EP4066836A1 (en) | 2014-08-18 | 2022-10-05 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
| AR103636A1 (es) | 2015-02-05 | 2017-05-24 | Teva Pharmaceuticals Int Gmbh | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol |
| EP3310375A4 (en) | 2015-06-22 | 2019-02-20 | Ampio Pharmaceuticals, Inc. | USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES |
| EP3529245A4 (en) | 2016-10-24 | 2020-12-23 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THE LATEST |
| MA47212A (fr) | 2017-01-06 | 2019-11-13 | Yumanity Therapeutics Inc | Méthodes de traitement de troubles neurologiques |
| WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
| ES3043183T3 (en) | 2018-03-23 | 2025-11-25 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| CN108570039B (zh) * | 2018-04-25 | 2022-09-23 | 上海美迪西生物医药股份有限公司 | 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用 |
| MA54829A (fr) | 2019-01-24 | 2021-12-01 | Yumanity Therapeutics Inc | Composés et leurs utilisations |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| US12486250B2 (en) | 2019-12-06 | 2025-12-02 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| CN115772127B (zh) * | 2023-01-31 | 2023-05-16 | 山东佰隆医药有限公司 | 一种合成2-氰基-5-溴嘧啶的方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA983493A (en) * | 1972-10-11 | 1976-02-10 | Gilbert Regnier | Procede de preparation des derives du benzodioxole |
| DE2341925A1 (de) * | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
| US4423049A (en) * | 1981-12-28 | 1983-12-27 | Mead Johnson & Company | 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines |
| JPS6143173A (ja) * | 1984-08-06 | 1986-03-01 | Mitsui Petrochem Ind Ltd | 新規ピリミジン誘導体およびその製法 |
| JPS6187672A (ja) * | 1984-10-08 | 1986-05-06 | Mitsui Petrochem Ind Ltd | 新規ピリミジン誘導体 |
| US4734418A (en) * | 1984-12-14 | 1988-03-29 | Mitsui Petrochemical Industries, Ltd. | Quinazoline compounds and antihypertensives |
| JPS61238784A (ja) * | 1985-04-17 | 1986-10-24 | Sumitomo Seiyaku Kk | コハク酸イミド誘導体及びその酸付加塩 |
| EP0257102B1 (en) * | 1986-02-24 | 1997-11-19 | Mitsui Petrochemical Industries, Ltd. | Agents for treating neurophathy |
| US5681956A (en) * | 1990-12-28 | 1997-10-28 | Neurogen Corporation | 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands |
| FR2701260B1 (fr) * | 1993-02-05 | 1995-05-05 | Esteve Labor Dr | Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments. |
| EP0793653A1 (en) * | 1994-11-23 | 1997-09-10 | Neurogen Corporation | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands |
| US6288230B1 (en) * | 1998-09-29 | 2001-09-11 | Neurogen Corporation | 2-(2, 3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands |
| EP1315831B8 (en) | 2000-02-24 | 2010-09-01 | Xenon Pharmaceuticals Inc. | Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
| GB0013383D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| ATE374765T1 (de) * | 2000-07-27 | 2007-10-15 | Lilly Co Eli | Substituierte heterocyclische amide |
| EP1322767B1 (en) | 2000-09-26 | 2008-07-23 | Xenon Pharmaceuticals Inc. | Methods and compositions employing a stearoyl-coa desaturase-hscd5 |
| EP1452525A4 (en) * | 2001-10-30 | 2005-01-26 | Nippon Shinyaku Co Ltd | AMIDE DERIVATIVES AND CORRESPONDING MEDICAMENTS |
| EP1456175A1 (en) * | 2001-12-07 | 2004-09-15 | Eli Lilly And Company | Substituted heterocyclic carboxamides with antithrombotic activity |
| WO2003068769A1 (en) * | 2002-02-12 | 2003-08-21 | Pfizer Inc. | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh) |
| CA2476583C (en) * | 2002-03-13 | 2011-07-05 | Kristof Van Emelen | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| WO2003076401A1 (en) | 2002-03-13 | 2003-09-18 | Janssen Pharmaceutica N.V. | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
| ES2306859T3 (es) * | 2002-03-13 | 2008-11-16 | Janssen Pharmaceutica Nv | Derivados de sulfonil como nuevos inhibidores de histona deacetilasa. |
| CA2483314A1 (en) * | 2002-04-25 | 2003-11-06 | Pharmacia Corporation | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| GB0209715D0 (en) * | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| PL1633724T3 (pl) * | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| EP2316827B1 (en) * | 2003-07-30 | 2016-01-27 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
-
2004
- 2004-07-29 KR KR1020067002003A patent/KR20060037409A/ko not_active Ceased
- 2004-07-29 US US10/567,009 patent/US7456180B2/en not_active Expired - Fee Related
- 2004-07-29 CA CA002533901A patent/CA2533901A1/en not_active Abandoned
- 2004-07-29 SG SG200805680-6A patent/SG145701A1/en unknown
- 2004-07-29 PL PL04779656T patent/PL1651620T3/pl unknown
- 2004-07-29 AU AU2004261268A patent/AU2004261268B2/en not_active Ceased
- 2004-07-29 PT PT04779656T patent/PT1651620E/pt unknown
- 2004-07-29 RU RU2006105717/04A patent/RU2006105717A/ru not_active Application Discontinuation
- 2004-07-29 EP EP10184745A patent/EP2316828A1/en not_active Withdrawn
- 2004-07-29 CN CNA2004800219422A patent/CN1829701A/zh active Pending
- 2004-07-29 WO PCT/US2004/024658 patent/WO2005011657A2/en not_active Ceased
- 2004-07-29 SI SI200431805T patent/SI1648874T1/sl unknown
- 2004-07-29 CN CNB200480021867XA patent/CN100558713C/zh not_active Expired - Fee Related
- 2004-07-29 BR BRPI0412348-4A patent/BRPI0412348A/pt not_active IP Right Cessation
- 2004-07-29 AT AT04779656T patent/ATE532772T1/de active
- 2004-07-29 ES ES04779656T patent/ES2377406T3/es not_active Expired - Lifetime
- 2004-07-29 CN CN200910207686A patent/CN101693697A/zh active Pending
- 2004-07-29 JP JP2006522096A patent/JP4838128B2/ja not_active Expired - Fee Related
- 2004-07-29 EP EP04779656A patent/EP1651620B1/en not_active Expired - Lifetime
-
2006
- 2006-01-05 ZA ZA200600125A patent/ZA200600125B/en unknown
- 2006-01-05 ZA ZA200600126A patent/ZA200600126B/en unknown
- 2006-01-25 EC EC2006006311A patent/ECSP066311A/es unknown
- 2006-01-26 IL IL173396A patent/IL173396A0/en unknown
- 2006-01-27 TN TNP2006000033A patent/TNSN06033A1/en unknown
- 2006-02-27 MA MA28838A patent/MA28010A1/fr unknown
- 2006-02-28 NO NO20060971A patent/NO20060971L/no not_active Application Discontinuation
-
2008
- 2008-10-08 US US12/247,792 patent/US8030488B2/en not_active Expired - Fee Related
-
2009
- 2009-06-11 AU AU2009202338A patent/AU2009202338A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6353460B2 (ja) | Ｈｂｖ感染に対する抗ウイルス剤としての官能化ベンズアミド誘導体 | |
| CN103450077B (zh) | IRE-1α抑制剂 | |
| TWI236474B (en) | Antagonists of MCP-1 function and methods of use thereof | |
| TWI339121B (en) | 1-piperazine- and 1-homopiperazine-carboxylate derivatives, preparation and therapeutic application thereof | |
| JP2008513516A5 (enExample) | ||
| RU2493149C2 (ru) | Замещенные метилфенилкетоны, пригодные для использования в качестве ингибиторов pde4 | |
| JP2010528114A (ja) | 脂肪酸アミド加水分解酵素のヘテロアリール置換尿素モジュレータ | |
| AU2016323305A1 (en) | Hepatitis B core protein modulators | |
| JP2008513515A5 (enExample) | ||
| RU2006105717A (ru) | Производные пиперазина и их применение в качестве терапевтических агентов | |
| AU2014310404B2 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
| AU2018216954A1 (en) | Piperazine derivatives for influenza virus inhibition | |
| JP2005514455A (ja) | 芳香族チオエーテル肝臓ｘ受容体モジュレータ | |
| PT1142885E (pt) | Derivados de 2-(n-cianoimino)tiazolidin-4-ona | |
| EP3154634B1 (en) | Imidazol- or 1,2,4-triazol-derivatives and their use | |
| CN110885318A (zh) | 苯并恶唑衍生物及其制备方法和应用 | |
| CN102516113B (zh) | 系列联苯醚衍生物以及在制备抗结核病药物方面的用途 | |
| WO2019105234A1 (zh) | 芳香族化合物及其药物组合物和用途 | |
| WO2004069788A1 (ja) | カルボン酸化合物 | |
| BR112014028632B1 (pt) | composto, composição farmacêutica, e, método para preparar um composto | |
| JP7620629B2 (ja) | ＰＤＩＡ４阻害剤及びβ細胞発症機序を阻害し、糖尿病を治療するためのこのＰＤＩＡ４阻害剤の使用 | |
| WO2014092514A1 (ko) | 신규한 화합물, 이의 약학적으로 허용가능한 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물 | |
| JP2008515884A (ja) | 新規なヒドロキシメチルベンゾチアゾールアミド | |
| JP2010529171A (ja) | 新規化合物 | |
| WO2017042380A1 (en) | Novel 5-amino-2-thioimidazole compounds and their use |